An observational study in Gestational Diabetes, sponsored by University Hospital Tuebingen. Recruiting at 1 site in Germany. Open to female participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2022-08-22.
Sponsored by University Hospital Tuebingen · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 13 studies in Diabetes, Gestational with a site in Germany — 6 open to participants now, 6 under way, none of them phase 3. Diabetes, Gestational · Germany.
Among the 13 studies in Diabetes, Gestational with a site in Germany, this one is the only one that started in 2012, is one of 6 observational ones, and was the 6th registered.
878 studies on the registry are indexed under Diabetes, Gestational; 196 are open to participants now.
Browse Diabetes, Gestational studies →6 of the 13 studies in Diabetes, Gestational with a site in Germany are open now. Recruiting first, the newest first:
Bionime Corporation · Sites in Germany
Ages 18+ · Women only
University of Ulm · Sites in Germany
Ages 18+ · Healthy volunteers
Jena University Hospital · Sites in Germany
Ages 18+ · Women only
Charite University, Berlin, Germany · Sites in Germany
Ages 18–45 · Women only · Healthy volunteers
University of Ulm · Sites in Germany
Ages 18+ · Women only · Healthy volunteers
A study can be open while its sites in Germany have not opened yet or have stopped. Only those recruiting at a site in Germany →
Of the 132 Diabetes, Gestational studies recruiting now, 60 (45%) set no upper age limit and 70 (53%) stop at 75 or younger; 12 take children under 18; 60 take healthy volunteers.
This study: 18 Years and older · female · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
13 studies; the count open now beside each. This study's row is marked.
First in 2008; this study’s year is marked. 1 started in 2012.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 800 is above the median of 175 across 290 observational studies indexed under Diabetes, Gestational.
Median enrollment 100 across the 7 interventional studies, 450 across the 6 observational. Of the 3 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
2 of 13 have an industry lead sponsor. The 9 most frequent:
University Hospital Tuebingen is the lead sponsor of 492 studies on the registry; 110 are open to participants now.
University Hospital Tuebingen has 2 studies filed under Diabetes, Gestational — fewer than ten, so there is no comparison to draw.
3 of the studies in Diabetes, Gestational with a site in Germany that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07889388Bionime CorporationRIGHTEST iFree 2 CGM in Pregnant Women With Diabetes Study | 2027-03 |
| NCT04270578University Hospital TuebingenGestational Diabetes | 2027-05-01 |
| NCT03313024Charite University, Berlin, GermanyBerlin-Brandenburg Pregnancy Cohort | 2027-10 |
Add all 3 to your calendar (.ics) → With an account.
Among the 13 studies in Diabetes, Gestational with a site in Germany, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Due to a changed lifestyle with less physical activity, unfavorable diets rich in fat and calories and obesity, the prevalence of diabetes mellitus is increasing worldwide. The diabetes epidemic is associated with significant personal and socio-economic consequences. Despite attempts to prevent the complications of diabetes, this disease is still the leading cause of blindness, chronic renal insufficiency and non-traumatic amputation. It is important to detect early on an increase in blood sugar and treat it accordingly to reduce costs and to minimize the personal suffering of those affected. As the number of patients with type 2 diabetes mellitus continues to rise, the number of young women with gestational diabetes mellitus (GDM) also increases. This is a disorder og glucose metabolism, which occurs for the first time in pregnancy. The causes for this are manifold. Among other causes, the increasing age of the mothers and weight gain during pregnancy are risk factors for gestational diabetes. Although it has been recommended that women with gestational diabetes should be re-examined after the birth of their child, many women have not. The study is a follow-up study to clarify whether insulin secretion disorder in women with and after GDM is a risk factor for the occurrence of type 2 diabetes mellitus.
Pregnant women in gestational week 24+0 till 31+6 and women postpartum who had a documented occurence of GDM in previous pregnancy.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Enrollment is possible during AND after gestation:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Glucose tolerance during 75 g oral glucose tolerance test
Glucose tolerance, insulin sensitivity and insulin secretion during oral glucose tolerance test
Time frame: Glycemia from start of glucose tolerance test (0 minutes) until the end (120 minutes)
Glucose tolerance during 75 g oral glucose tolerance test 1, 2, 5, 10 years postpartum
Glucose tolerance during oral glucose tolerance test
Time frame: Glycemia from start of glucose tolerance test (0 minutes) until the end (120 minutes)
Body fat distribution
Measurement of body fat distribution by MRS
Time frame: Once during pregnancy and 1, 2, 5, and 10 years postpartum
Spiroergometry to assess physical fitness
Measurement of VO2max (l/min/kg) as a proxy for physical fitness
Time frame: 1, 2, 5, and 10 years postpartum
BIA (bioimpedance analysis)
BIA to estimate body fat (%)
Time frame: Once during pregnancy and 1, 2, 5, and 10 years postpartum
BMI
Measurement of weight (kg) and height (m) and given as kg/m\^2
Time frame: Once during pregnancy and 1, 2, 5, and 10 years postpartum
Assessment of cognitive abilities in offspring
Cognitive skills represented as an intelligence quotient will be assessed Wechsler Intelligence Scale for Children - Fifth Edition (WISC-V)
Time frame: 6 and 10 years postpartum
Assessment of cognitive, motoric and language development in offspring
Cognitive, motoric and language development of children will be assessed with the Bayley Scales of Infant and Toddler Development - Third Edition (Bayley-III)
Time frame: 2 years postpartum
BIA in offspring
BIA to estimate body composition in offspring
Time frame: 2, 6 and 10 years postpartum
Electrocardiogram
10 minute ECG to assess RR distance for calculation of heart rate variability (R wave distance in ms)
Time frame: 2, 6 and 10 years postpartum
blood sample
blood sample to assess HbA1C
Time frame: 6 and 10 years postpartum
Plan to share: No
Started May 2012 (actual). Primary completion is estimated for May 2027, 179 months after the start.
Of 142 non-industry observational studies under Diabetes, Gestational, half reached primary completion within 42 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 70. This study's planned 179 months is above that.
Counting every sponsor, half of 144 studies reached it within 43 months; a quarter within 19 and three quarters within 73.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University Hospital Tuebingen →